The evidence for the efficiency and safety of dapoxetine in treating premature ejaculation
| Autor: | I P Matyukhov, N D Akhvlediani |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
Drug Benzylamines media_common.quotation_subject Naphthalenes Placebo 03 medical and health sciences 0302 clinical medicine Premature ejaculation medicine Humans In patient Clinical efficacy Premature Ejaculation media_common 030219 obstetrics & reproductive medicine business.industry General Medicine Dapoxetine Clinical Practice Safety profile 030220 oncology & carcinogenesis Anesthesia medicine.symptom business medicine.drug |
| Zdroj: | Urologiia. :106-110 |
| ISSN: | 1728-2985 |
| Popis: | The aim of the study is to assess the evidence on the efficacy and safety of dapoxetine in premature ejaculation (PE). The analysis includes results of randomized placebo-controlled trials, integrative reviews and one meta-analysis on the clinical efficacy and safety of dapoxetine. All studies have shown higher efficacy of dapoxetine in patients with PE compared with placebo. Its administration at a dosage of 30 and 60 mg results in an increase in the coitus duration up to approximately 3 and 3.5 minutes, respectively. The safety profile of dapoxetine allows using it in clinical practice. Dapoxetine is a novel and effective PE drug on the Russian market. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|